Moderna's mRNA-1083 Combo COVID-19 and Flu Vaccine Shows Stronger Immune Response in Phase 3 Trials

Jun 10, 2024, 11:10 AM

Moderna announced that its combination vaccine for COVID-19 and influenza generated a stronger immune response compared to separate shots against the two viruses. The investigational vaccine, mRNA-1083, showed positive results in a Phase 3 late-stage clinical trial, particularly in adults aged 50 and over. The Phase 3 data indicated that the combined vaccine is more effective than existing individual shots for both COVID-19 and flu. The company highlighted that the new vaccine could simplify immunization efforts by reducing the number of shots needed.